SAN DIEGO, Oct. 25, 2016 /PRNewswire/ -- Epic Sciences in collaboration with other industry, academic, and governmentpartners will contribute to the Blood Profiling Atlas pilot of the Cancer Moonshot Initiative championed by Vice President Biden and the White House. The Blood Profiling Atlas seeks to create an open database of results from liquid biopsy tests to accelerate
Epic Sciences, the only circulating tumor cell (CTC) company represented at the initial Blood Profiling Atlas, will contribute single cell phenotypic and genomic profiles of CTCs from metastatic cancer patients prior to, during, and at progression on standard of care therapeutics.
"Our No Cell Left Behind platform enables the analysis of CTCs as they evolve in response to cancer drugs that are administered," said Murali Prahalad PhD, president and CEO at Epic Sciences. "We are excited to be leveraging our technology and extensive biorepository of contemporary clinical specimens to accelerate tests that can improve patient outcomes."
Currently, Epic Sciences has received and processed over 25,000 blood samples through its partnership with 40 biopharma companies and 25 academic institutions. Insights gained through these collaborations have aided in the development of analytical and clinically-validated predictive tests.
"Of critical need is the ability to understand cancer therapy resistance through sub-clonal tumor evolution and heterogeneity," said Ryan Dittamore, vice president of translational research and clinical affairs at Epic Sciences. "We believe our single cell phenotypic and genomic characterization will provide novel and actionable insights regarding tumor progression and mechanisms of drug resistance in the context of therapeutic clinical decisions."
More on the Cancer Moonshot Blood Profiling Atlas: https://www.whitehouse.gov/sites/default/files/docs/fact_sheet_final_moonshot.pdf
About Epic Sciences Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences' mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic Sciences' no cell left behind® technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences' goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.
Further information is available on the Company's website, www.epicsciences.com. Stay in touch on Linkedin, on Twitter @EpicSciences or on Facebook.com/EpicSciences.
Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., email@example.com, +1.858.344.8091
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/epic-sciences-to-contribute-to-cancer-moonshot-blood-profiling-atlas-300350373.html
SOURCE Epic Sciences, Inc.
Subscribe to our Free Newsletters!
Blood groups are of four important groups determined by the presence or absence of specific ...
Spermatocele is a condition in which there is a blockage in the epididymal duct, resulting in semen ...
Be a blood donor and save lives for your donated blood is separated into blood products or just ...View All